HealthEquity price target raised to $110 from $100 at BTIG

BTIG raised the firm’s price target on HealthEquity to $110 from $100 and keeps a Buy rating on the shares after the company reported “excellent” Q4 results. HealthEquity continues to take share and the firm’s view is that HealthEquity is “actually delivering on improved trend results for plans,” the analyst tells investors in a post-earnings note. Higher yields will last for years, but HealthEquity is “not simply an interest-rate story,” adds the analyst, who says the company is delivering “very solid solutions to plans and employers that control spending trend.”